Lys227
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys227  -  GAPDH (human)

Site Information
VIPELNGkLtGMAFR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 461582

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 5 , 6 , 7 , 8 , 9 , 10 ) , mutation of modification site ( 4 )
Disease tissue studied:
colorectal cancer ( 6 , 7 ) , colorectal carcinoma ( 6 , 7 ) , leukemia ( 5 ) , chronic myelogenous leukemia ( 5 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) ( 4 ) , A549 (pulmonary) ( 8 ) , HCT116 (intestinal) ( 6 , 7 , 9 , 10 ) , HeLa (cervical) ( 1 ) , Jurkat (T lymphocyte) ( 2 , 8 ) , K562 (erythroid) ( 5 )

Downstream Regulation
Effects of modification on GAPDH:
intracellular localization ( 4 )

References 

1

Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51
23954790   Curated Info

2

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

3

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

4

Ventura M, et al. (2010) Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase is regulated by acetylation. Int J Biochem Cell Biol 42, 1672-80
20601085   Curated Info

5

Moritz A (2010) CST Curation Set: 9820; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

7

Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

8

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

9

Li Y (2005) CST Curation Set: 966; Year: 2005; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

10

Li Y (2005) CST Curation Set: 967; Year: 2005; Biosample/Treatment: cell line, HCT116/EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info